ESC adds St. Jude’s CardioMems to guidelines for directed HF therapy

The European Society of Cardiology has added St. Jude Medical‘s (NYSE:STJ) CardioMems heart failure system to its guidelines as a “directed therapy management and monitoring tool for heart failure patients,” the company said today. The CardioMems device consists of a wireless sensor implanted in the pulmonary artery via catheter to directly measure pressure in the vessel. The device is designed to help physicians manage patients’ medication to control their heart failure before visible changes to weight or blood pressure occur. The new guidelines, published this year, support the use of pulmonary artery pressure monitoring with the CardioMems HF system for the diagnosis and treatment of acute and chronic heart failure, St. Jude said. “The ESC guideline for the CardioMEMS HF System provides direction for physicians who are working to appropriately treat our heart failure patients and reduce their risk of repeated heart failure hospitalizations,” Dr. Giovanni Perego of Milan, Italy’s Istituto Auxologico Italiano said in a press release. The company said data from the Champion study of the device served as a base for the updated guideline, which the company says applies to all Class II heart failure patients, regardless of their ejection fraction. “We are very pleased to see the CardioMEMS HF System was included in the guidelines and congratulate the European Society of Cardiology for working to make this technology more widely availa...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular St. Jude Medical Source Type: news